With respect to synergy with chemotherapy, navitoclax (ABT-263) sensitized PC3 prostate cancer cells to docetaxel in vitro and in vivo, with the predominant impact through inhibition of BCL-XL [220]. The gene discussed is BCL2L1; the disease is Familial prostate cancer.